Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.72 |
| ▸ | KDR | P35968 | 15/20 | 0.64 |
| ▸ | RET | P07949 | 2/20 | 0.64 |
| ▸ | KIF5B | P33176 | 2/20 | 0.64 |
| ▸ | FGFR1 | P11362 | 11/20 | 0.63 |
| ▸ | FLT1 | P17948 | 11/20 | 0.63 |
| ▸ | FLT4 | P35916 | 9/20 | 0.63 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.60 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.60 |
| ▸ | TEK | Q02763 | 2/20 | 0.60 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.60 |
| ▸ | PLK4 | O00444 | 1/20 | 0.60 |
| ▸ | CIT | O14578 | 1/20 | 0.60 |
| ▸ | GAK | O14976 | 1/20 | 0.60 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.60 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.60 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.60 |
| ▸ | STK10 | O94804 | 1/20 | 0.60 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5450329 | 0.99 | EGFR (0.71) | EGFRKDRRETKIF5BFGFR1 | |
| SCHEMBL5446470 | 0.98 | EGFR (0.69) | EGFRKDRRETKIF5BFGFR1 | |
| Hydrochloric Acid SCHEMBL5456015 | 0.97 | EGFR (0.68) | EGFRKDRRETKIF5BFGFR1 | |
| SCHEMBL6976247 | 0.96 | EGFR (0.66) | EGFRKDRRETKIF5BFGFR1 | |
| SCHEMBL7083637 | 0.94 | EGFR (0.65) | EGFRKDRRETKIF5BFGFR1 | |
| SCHEMBL5453241 | 0.93 | KDR (0.69) | EGFRKDRRETKIF5BFGFR1 | |
| Hydrochloric Acid SCHEMBL5451307 | 0.92 | EGFR (0.70) | EGFRKDRRETKIF5BFGFR1 | |
| SCHEMBL5452360 | 0.92 | EGFR (0.68) | EGFRKDRRETKIF5BFGFR1 | |
| SCHEMBL5756707 | 0.91 | EGFR (0.78) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL14564688 | 0.91 | EGFR (0.78) | EGFRKDRFGFR1FLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7160889-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2007-01-09 | — | — | US | claimed |
| EP-1274692-B1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-08-02 | — | — | EP | claimed |
| US-20030191308-A1 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | US | claimed |
| US-20070066633-A1 | Quinazoline compounds | ASTRAZENECA AB | 2007-03-22 | — | — | US | disclosed |
| US-7160889-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2007-01-09 | — | — | US | disclosed |
| EP-1274692-B1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-08-02 | — | — | EP | disclosed |
| US-20030191308-A1 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | US | disclosed |
| EP-1274692-A1 | QUINAZOLINE COMPOUNDS | AstraZeneca AB (SE) | 2003-01-15 | — | — | EP | disclosed |
| WO-2001077085-A1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191308-A1 | Quinazoline compounds | CNR1, CBR1, CCR7 | EGFR 1629/4885KDR 85/4885RET 3257/4885 |
| US-20070066633-A1 | Quinazoline compounds | CCR7, CNR1, CBR3 | EGFR 1429/4885KDR 93/4885RET 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.